Calidi Biotherapeutics earnings release, August 13, 2026
Exhibit
99.1
Calidi
Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent
Business
Highlights
SAN
DIEGO, August 13, 2026 -
Calidi
Biotherapeutics,
Inc. (NYSE American: CLDI)
(“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today reported financial and operating results for the three months ended June 30, 2026, and reviewed recent business highlights.
“Throughout the second quarter,
Calidi continued to advance its RedTail platform and redefine the potential of oncolytic viruses and genetic medicine,” said Eric Poma,
Ph.D.,
Calidi
Biotherapeutics CEO. “We anticipate CLD-401, the lead drug candidate from our RedTail platform, entering the clinic during the first quarter of 2027. In addition, we have expanded what the RedTail platform can do with our new approach of in situ
T-cell engagers.”
Second
Quarter 2026 and Recent
Business
Developments
Second
Quarter 2026 Financial Results
Calidi reported a net loss attributable to common stockholders of $4.2 million, or $2.94 per share, for the second quarter of
2026, compared with a net loss attributable to common stockholders of $5.7 million, or $31.75 per share, for the same period in 2025.
Prior-period share and per-share amounts have been adjusted to reflect the Company’s 1-for-16 reverse stock split completed in July 2026.
Research and development expenses were $2.6 million for the second quarter of 2026, unchanged from the second quarter of 2025.
General and administrative expenses were $1.6 million for the second quarter of
2026, compared with
$3.1 million for the comparable period in 2025.
The
Company had $4.1 million in cash and $0.2 million in restricted cash as of June 30, 2026, compared with
$5.6 million in cash and $0.2 million in restricted cash as of December 31, 2025.
About
Calidi Biotherapeutics
Calidi
Biotherapeutics (NYSE American: CLDI) is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The Company’s proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. This advanced enveloped technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations.
CLD-401, the lead candidate from the RedTail platform, currently in IND-enabling studies, targets metastatic non-small cell lung cancer, head and neck cancer, and other tumor types with high unmet medical need. Calidi continues to advance its pipeline utilizing the RedTail platform including its novel approach to incorporate in situ T-cell engagers in solid tumors.
Calidi
Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com or view Calidi’s
Corporate Presentation here.
Forward-Looking
Statements
Financial statements
Income Statement
Three Months Ended June 30, — (In thousands, except per share data)
| Three Months Ended June 30, – 2026 – (Unaudited) | Three Months Ended June 30, – 2025 – (Unaudited) | ||
|---|---|---|---|
| OPERATING EXPENSES | Research and development | 2,558 | 2,593 |
| OPERATING EXPENSES | General and administrative | 1,592 | 3,071 |
| OPERATING EXPENSES | Total operating expense | 4,150 | 5,664 |
| OPERATING EXPENSES | Loss from operations | -4,150 | -5,664 |
| OTHER INCOME (EXPENSE), NET | Interest expense | -29 | -29 |
| OTHER INCOME (EXPENSE), NET | Interest expense – related party | -6 | -23 |
| OTHER INCOME (EXPENSE), NET | Change in fair value of other liabilities and derivatives | -1 | -18 |
| OTHER INCOME (EXPENSE), NET | Change in fair value of other liabilities and derivatives – related party | -1 | |
| OTHER INCOME (EXPENSE), NET | Other income (expense), net | 31 | -22 |
| OTHER INCOME (EXPENSE), NET | Total other expense, net | -5 | -93 |
| OTHER INCOME (EXPENSE), NET | LOSS BEFORE INCOME TAXES | -4,155 | -5,757 |
| OTHER INCOME (EXPENSE), NET | Income tax provision | -5 | -4 |
| OTHER INCOME (EXPENSE), NET | NET LOSS | -4,160 | -5,761 |
| OTHER INCOME (EXPENSE), NET | Net loss attributable to noncontrolling interest | -46 | |
| OTHER INCOME (EXPENSE), NET | NET LOSS ATTRIBUTABLE TO CONTROLLING INTEREST | -4,160 | -5,715 |
| OTHER INCOME (EXPENSE), NET | NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS | -4,160 | -5,715 |
| OTHER INCOME (EXPENSE), NET | Net loss per share; basic and diluted | -2.94 | -31.75 |
| OTHER INCOME (EXPENSE), NET | Weighted average common shares outstanding; basic and diluted | 1,416 | 180 |
Balance Sheet
June 30, 2026 — ( In thousands, except for par value data )
| June 30, 2026 – (Unaudited) | December 31, 2025 | ||
|---|---|---|---|
| CURRENT ASSETS | Cash | 4,071 | 5,600 |
| CURRENT ASSETS | Prepaid expenses and other current assets | 1,357 | 656 |
| CURRENT ASSETS | Total current assets | 5,428 | 6,256 |
| NONCURRENT ASSETS | Machinery and equipment, net | 775 | 781 |
| NONCURRENT ASSETS | Operating lease right-of-use assets, net | 992 | 1,682 |
| NONCURRENT ASSETS | Other noncurrent assets | 9 | 138 |
| NONCURRENT ASSETS | TOTAL ASSETS | 7,204 | 8,857 |
| CURRENT LIABILITIES | Accounts payable | 930 | 595 |
| CURRENT LIABILITIES | Related party accounts payable | 18 | |
| CURRENT LIABILITIES | Accrued expenses and other current liabilities | 1,131 | 1,276 |
| CURRENT LIABILITIES | Related party accrued expenses and other current liabilities | 530 | |
| CURRENT LIABILITIES | Finance lease liability, current | 167 | 111 |
| CURRENT LIABILITIES | Operating lease right-of-use liability, current | 1,009 | 1,405 |
| CURRENT LIABILITIES | Total current liabilities | 3,237 | 3,935 |
| NONCURRENT LIABILITIES | Operating lease right-of-use liability, noncurrent | 5 | 277 |
| NONCURRENT LIABILITIES | Finance lease liability, noncurrent | 161 | 171 |
| NONCURRENT LIABILITIES | Promissory note | 600 | 600 |
| NONCURRENT LIABILITIES | Warrant liability | 63 | 107 |
| NONCURRENT LIABILITIES | Related party warrant liability | 5 | 8 |
| NONCURRENT LIABILITIES | TOTAL LIABILITIES | 4,071 | 5,098 |
| NONCURRENT LIABILITIES | TOTAL EQUITY | 3,133 | 3,759 |
| NONCURRENT LIABILITIES | TOTAL LIABILITIES AND TOTAL EQUITY | 7,204 | 8,857 |
Full release
This press release may contain forward-looking statements for purposes of the “safe harbor” provisions under the United States
Private Securities Litigation Reform Act of 1995. Terms such as “anticipates,” “believe,” “continue,”
“could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,”
“possible,” “potential,” “predicts,” “project,” “should,” “towards,”
“would” as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, the Company’s plans strategies, priorities and key operational initiatives for fiscal year 2026 and 2027, including the Company’s plan to dose the first patient in a phase
1 trial in Q1 2027, statements concerning key milestones, including certain pre-clinical data, planned clinical trials, and statements relating to the safety and efficacy of Calidi’s therapeutic candidates in development. Any forward-looking statements contained in this discussion are based on Calidi’s current expectations and beliefs concerning future developments and their potential effects and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials, the risk that early results of clinical trials do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive review of the data, and as more patient data becomes available, the risk that Calidi may not receive FDA approval for some or all of its therapeutic candidates; and, with respect to the Company’s fiscal year 2026 and 2027 initiatives, including the timing and ability to open a phase 1 clinical study in Q1 2027, the risk that actual results may differ materially due to, among other things, the timing, cost and results of research and development activities and preclinical studies; interactions with, and the timing and substance of feedback from, regulatory authorities (including that any preliminary interactions with the FDA may not be indicative of future outcomes or regulatory success); changes in applicable laws or regulations; manufacturing and supply chain matters; the availability of capital and other resources; and changes in business, market, economic or competitive conditions. Other risks and uncertainties are set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s... (truncated)mended or supplemented by other reports we file with the
SEC from time to time. We disclaim any obligation to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.
Investors
Contact:
IR@calidibio.com
Media
Contact:
PR@calidibio.com
CALIDI
BIOTHERAPEUTICS, INC.